As illustrated in Figs. 2C & S2B, the treatment with CMs from glioma cells resulted in elevated expressions of M2-macrophage markers CD206 and CD163, while showing no significant alterations in the M1-macrophage markers CD80 and CD86. Here, CD80 is linked to glioma.